NCT02530034 - Hu8F4 in Treating Patients With Advanced Hematologic Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2019

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions

Acute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeBlast Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveHematopoietic and Lymphoid Cell NeoplasmHigh Risk Myelodysplastic SyndromeMyelodysplastic Syndrome With Excess Blasts-1Myelodysplastic Syndrome With Excess Blasts-2MyelofibrosisRecurrent Acute Myeloid LeukemiaRecurrent Chronic Myelomonocytic LeukemiaRefractory Chronic Myelomonocytic LeukemiaSecondary Acute Myeloid Leukemia

Interventions

DRUG

Anti-PR1/HLA-A2 Monoclonal Antibody Hu8F4

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

Trial Locations (4)

10467

Montefiore Medical Center, Albert Einstein College of Medicine, The Bronx

30912

Augusta University, Augusta

77030

M D Anderson Cancer Center, Houston

84112

Huntsman Cancer Institute, Salt Lake City

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER